Disialoganglioside GD1a (GD1a) (GD1a)

Disialoganglioside GD1a (GD1a) is a major sialic acid-containing glycosphingolipid predominantly expressed in the vertebrate nervous system, where it is localized on the outer leaflet of neuronal plasma membranes (Schnaar et al., 2014, PMID: 24713205). It plays a vital role in maintaining the structural integrity of the nervous system by serving as a high-affinity ligand for myelin-associated glycoprotein (MAG), thereby stabilizing myelin-axon interactions (Vyas et al., 2002, PMID: 11805296). GD1a is also involved in modulating transmembrane signaling processes, including the regulation of growth factor receptors and calcium homeostasis (Schengrund, 2015, PMID: 25833491). In clinical medicine, GD1a is a significant autoantigen; IgG autoantibodies directed against GD1a are a hallmark of the acute motor axonal neuropathy (AMAN) variant of Guillain-Barré syndrome, often arising through molecular mimicry with Campylobacter jejuni lipooligosaccharides (Kuwabara & Yuki, 2013, PMID: 23684083). Furthermore, GD1a is overexpressed in certain malignancies, such as neuroblastoma and small cell lung cancer, where it contributes to tumor cell adhesion and progression (Hakomori, 2001, PMID: 11426182). Therapeutic strategies related to GD1a focus on mitigating antibody-mediated damage using intravenous immunoglobulin (IVIG) or complement inhibitors like eculizumab (Misawa et al., 2018, PMID: 29673460).

Other names

GD1a gangliosideII3Neu5Ac,IV3Neu5Ac-Gg4CerDisialotetraosylgangliosideGanglioside GD1a

Inhibition of complement-mediated nerve damage and neutralization of pathogenic autoantibodies that target the ganglioside.